Tempest Therapeutics, Inc.(TPST)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Tempest Therapeutics, Inc. (TPST) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TPST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.7m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Tempest Therapeutics, Inc. reports net income of $-5.2M, free cash flow of $-2.8M. Top institutional holders of TPST by reported 13-F value include SABBY MANAGEMENT, Versant Venture Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. TPST trades on the Nasdaq exchange and files with the SEC under CIK 1544227. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TPST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tempest Therapeutics, Inc. directly from SEC EDGAR.
Net Income
$-5.2M
Free Cash Flow
$-2.8M
TPST key financials by period
Tempest Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2017
10-K
$295.0K
$-84.6M
—
FY 2016
10-K
$653.0K
$-82.3M
—
FY 2015
10-K
$277.0K
$-73.2M
—
Institutions holding TPST
Institutional investors reporting a position in Tempest Therapeutics, Inc. on SEC Form 13F.
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.7M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Price Chart
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
